CD274 and non-small cell lung carcinoma: Immunotherapies, represented by immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1), have revolutionized the treatment of advanced NSCLC and became the cornerstone of first-line therapy for tumors without a targetable driver alteration.1